David Moller has joined Sigilon Therapeutics to become the company’s chief scientific officer. Moller comes to the Cambridge, MA, drug developer from Eli Lilly (NYSE: [[ticker:LLY]]), where he was vice president of business development for emerging technology and innovation. Last year, Sigilon raised $23.5 million in a Series A financing round to bring its technology for encapsulating therapeutic proteins into clinical testing.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
